Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | GHSR | Q92847 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.45 |
| ▸ | FASN | P49327 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3221724 | 0.96 | POLB (0.49) | HPGDMAPK1GHSRPOLBSMN1; SMN2 | |
| SCHEMBL3224806 | 0.81 | MEN1 (0.71) | MAPK1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL3210771 | 0.81 | HPGD (0.53) | HPGDMAPK1GHSR | |
| SCHEMBL3218211 | 0.80 | SIGMAR1 (0.56) | HPGDMAPK1GHSRPOLB | |
| SCHEMBL3218307 | 0.77 | SMN1; SMN2 (0.51) | HPGDMAPK1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL774880 | 0.76 | KDM1A (0.57) | — | |
| SCHEMBL3216306 | 0.73 | TSHR (0.71) | KMT2ATSHR | |
| SCHEMBL7069417 | 0.73 | HPGD (0.68) | HPGDMAPK1POLBSMN1; SMN2MEN1 | |
| SCHEMBL3222628 | 0.73 | MAPK14 (0.51) | LMNAL3MBTL1L3MBTL3 | |
| Bromide SCHEMBL11386071 | 0.71 | BLM (0.60) | HPGDPOLBSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | claimed |
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004701-A1 | Topoisomerase inhibitors | TOP1, TOP2A, TOP2B | HPGD 1778/4885MAPK1 2955/4885GHSR 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.